Biopharma: Clinical Trial Pipeline Tracker – Key Catalysts from New Initiations, Recruitment Completion, and Trial Delays

Core Conclusions

The past week (May 13–20) produced meaningful pipeline signals for covered biopharma names. Argenx initiated a Phase 3 for efgartigimod in Graves‘ disease, extending its FcRn franchise beyond myasthenia gravis. Pfizer advanced berobenatide into Phase 3 obesity and completed enrollment for its CDK4 inhibitor in breast cancer. Amgen’s Xaluritamig completed enrollment in metastatic prostate cancer, moving a key asset toward data. On the cautionary side, Biohaven’s Phase 1 for BHV-1300 in Graves’ disease was delayed, and Neurocrine downsized its Phase 3 schizophrenia trial, signaling potential enrollment or feasibility concerns. These changes collectively point to an intensifying obesity/ metabolic competition, a broadening autoimmune pipeline from FcRn modulation, and modest oncology momentum, offset by select delays that may push readouts.

New Trial Initiations: Obesity and Autoimmune Expansion

Pfizer initiated a Phase 3 obesity trial for berobenatide (PF-08653944) targeting 954 participants with overweight/obesity, primary completion May 2028. This places Pfizer directly in the GLP-1/ incretin race, albeit with a timeline that lags leaders. Eli Lilly initiated a Phase 2 weight management study combining macupatide and eloralintide (400 patients, primary Sep 2027), adding to its already deep metabolic pipeline.

Argenx launched two new efgartigimod trials: a Phase 2 in autoimmune encephalitis (170 patients, Dec 2030) and a Phase 3 in Graves' disease (230 patients, Jun 2028). These represent meaningful label expansion beyond generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Regeneron initiated a Phase 1/2 for REGN15505 (PSMAx4-1BB) in prostate and renal cancer (265 patients) and a Phase 1 for REGN20934 in overweight/obesity (90 patients), demonstrating breadth across immuno-oncology and metabolic disease.

Investment implication: Argenx’s Graves’ disease Phase 3 is the most consequential new start—if successful, it could add a multi-billion-dollar indication. Pfizer’s obesity entry reinforces the market’s prize, but timeline risk is high. Lilly’s continued metabolic trial activity underscores its pipeline depth.

Enrollment Milestones: Key Data Readouts Approaching

Amgen completed recruitment for the Phase 3 XALute trial (NCT06691984) of xaluritamig vs cabazitaxel in metastatic castration-resistant prostate cancer (707 patients, primary Jan 2029). This is a high-stakes readout for Amgen’s bispecific T-cell engager platform. Pfizer completed recruitment for Phase 3 PF-07220060 (atirmociclib) with letrozole in HR+ HER2- breast cancer (1,035 patients, primary Jan 2029), a CDK4 inhibitor that could compete with palbociclib/ abemaciclib.

Merck began recruiting for Phase 3 adjuvant intismeran (V940) with/without pembrolizumab in high-risk stage I NSCLC (876 patients, primary Aug 2034). This is a major mRNA-based cancer vaccine trial. Regeneron also began recruitment for the Phase 2 EMPIRE study of cemiplimab ± fianlimab in colorectal cancer with MRD (79 patients, primary Apr 2029).

Completed trials: Lilly’s Phase 2 LY3549492 obesity study completed (288 patients), and Maplight’s Phase 2 ML-004 in autism completed (168 patients). These open the door to disclosure.

Investment implication: Amgen’s XALute enrollment completion sets up a potential survival benefit readout in 2028–2029. Merck’s intismeran trial is a long-duration catalyst but signals commitment to personalized vaccines. Investors should watch for top-line data from Maplight’s autism study.

Delays and Sizing Changes: Risk Signals Emerge

Biohaven’s Phase 1 for BHV-1300 in Graves’ disease was delayed (primary pushed from Sep 2026 to Sep 2027). This is a direct competitor to Argenx’s efgartigimod in the same indication, and the delay gives Argenx a first-mover advantage. Neurocrine downsized its Phase 3 NBI-1117568 schizophrenia trial from 800 to 600 patients (primary Dec 2031), a modest reduction but potentially indicative of enrollment challenges.

Other delays: AbbVie’s ubrogepant Phase 3 in adolescent migraine pushed from May 2026 to May 2027. Bristol-Myers’ afimetoran Phase 2 in SLE pushed from Mar 2026 to Jun 2026. BeOne Medicines’ Phase 1 BGB-B2033 combination trial delayed from Oct 2026 to May 2028 and simultaneously upsized from 140 to 392 patients—suggesting expanded cohort design, not necessarily negative.

Downsizing: AbbVie’s Phase 1 ABBV-295 obesity study cut from 96 to 48 patients, and Merck’s Phase 1 LVGN6051 combo trial cut from 276 to 105 upon completion.

Investment implication: Biohaven’s delay is a clear positive for Argenx in Graves’ disease. Neurocrine’s reduction is a minor negative but not decisive. The upsizing of BeOne’s Phase 1 is intriguing—investors should monitor for data.

Key Risks

• Clinical trial failure risk applies to all new initiations; obesity and autoimmune trials have high regulatory hurdles.
• Competitive dynamics: Argenx’s Graves’ disease Phase 3 will face eventual competition from Biohaven and others; Pfizer’s obesity entry will compete with Lilly/ Novo Nordisk.
• Enrollment and timeline risk: Delays are common; the Biohaven delay and Neurocrine downsizing highlight operational challenges.
• Data disclosure timing: Most readouts are 2-4 years away, limiting near-term catalysts.

Valuation / Trade Implications

No explicit rating changes. For long-only portfolios, Argenx (ARGX) benefits from the Graves’ Phase 3 start and competitor delay—its FcRn platform is undervalued relative to expanded indications. Amgen (AMGN) has a potential catalyst from XALute enrollment completion. Pfizer (PFE) obesity trial is early but adds optionality. Merck (MRK) continues to build its adjuvant mRNA franchise. Regeneron (REGN) has multiple early-stage shots on goal. Investors should monitor Biohaven for future read-through on Argenx.